Senti Bio to Present Key Clinical Data at AACR Annual Meeting
Senti Biosciences, Inc. (NASDAQ: SNTI), a pioneering clinical-stage biotechnology company specializing in innovative cell and gene therapies through its proprietary Gene Circuit platform, is set to host a conference call and webcast. The event will discuss the important new clinical data regarding their SENTI-202 Phase 1 trial, which will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting.
Details of the Conference Call and Webcast
The conference call is scheduled for Monday, April 28 at 8:30 AM ET. Timothy Lu, MD, PhD, the Chief Executive Officer and Co-Founder of Senti Bio, alongside Kanya Rajangam, MD, PhD, the President and Chief Medical Officer, will lead the discussion. This interactive session is designed for investors and stakeholders interested in the latest advancements in cancer therapy.
How to Join the Call
To participate, callers can dial (877) 524-8416 for domestic access or +1 (412) 902-1028 for international attendees. Additionally, the webcast will be accessible on Senti Bio's website and will remain archived for 90 days following the live event, ensuring that all interested parties have the opportunity to catch up on the insights shared.
Innovative Therapies at the Forefront of Cancer Treatment
Senti Bio is actively working on developing next-generation therapies aimed at combating incurable diseases, leveraging their advanced synthetic biology platform known as Gene Circuits. This innovative approach is at the heart of their mission to create unique therapies that are both precise and effective.
About SENTI-202
The lead program, SENTI-202, focuses on a pioneering off-the-shelf CAR NK cell therapy that selectively targets CD33 or FLT3 while sparing healthy cells, showcasing Senti Bio’s dedication to creating specialized treatments. The ongoing Phase 1 clinical trial is currently enrolling patients and aims to validate this promising approach. The Gene Circuits designed by Senti Bio are engineered to precisely eliminate cancerous cells while preserving healthy tissue, a crucial advancement in cancer treatment strategy.
The Future of Gene Circuit Technology
As Senti Bio continues to innovate within the biotechnology field, they are exploring new avenues for Gene Circuit application beyond oncological indications. This includes potential therapeutic solutions for a variety of diseases, further signifying the breadth of Senti Bio's capabilities and commitment to patient care. Their research advances not only cell therapies but also the development of gene therapies, providing a dual line of defense against various diseases.
Commitment to Innovation and Collaboration
Looking ahead, Senti Bio is focused on expanding its partnerships to enhance the scope of its Gene Circuit capabilities. Collaborations with various institutes and research organizations are expected to bolster their efforts in rapidly advancing their therapeutic pipeline. The goal remains clear: to provide groundbreaking treatment options that could profoundly improve patient outcomes.
Investor Relations and Support
Senti Bio maintains a strong commitment to investor engagement and transparency. Interested stakeholders can reach out to their dedicated investor relations team for further inquiries or details regarding the ongoing clinical studies and overall corporate updates. The team emphasizes the importance of maintaining open lines of communication with the investor community as they navigate the dynamic landscape of biotechnology.
Frequently Asked Questions
What is Senti Bio's mission?
Senti Bio aims to develop advanced cell and gene therapies to treat complex diseases, leveraging their proprietary Gene Circuit technology.
When is the conference call scheduled?
The conference call is scheduled for April 28th at 8:30 AM ET.
How can I access the webcast?
The webcast can be accessed through Senti Bio's website under the Investors section, and it will be archived for 90 days post-event.
What is the SENTI-202 program?
SENTI-202 is Senti Bio's first-in-class CAR NK cell therapy targeting specific cancer cell types to increase therapeutic precision and minimize damage to healthy cells.
How can investors contact Senti Bio?
Investors can reach out to JTC Team, LLC, specifically Jenene Thomas, at (908) 824-0775 or via email at SNTI@jtcir.com for inquiries.
